China Trading Desk Launches Comprehensive China Travel Dashboard Amid Rising Outbound Travel
25.7.2023 10:27:00 EEST | Business Wire | Press release
China Trading Desk, a premier provider of marketing and advertising solutions for the Chinese market, is proud to announce the release of our game-changing tool - the China Travel Dashboard. Built to provide unparalleled insights into the evolving attitudes, expectations, and behaviours of outbound travellers from China, this dashboard is born out of our deep understanding of the Chinese market, a sector that has witnessed a remarkable upward trajectory in recent years.
Our newly launched China Travel Dashboard is designed to act as a compass, helping our clients navigate the complexity of this dynamic market. The dashboard brings a treasure trove of critical information to your fingertips, transforming it into a must-have tool for formulating and executing digital marketing campaigns aimed at Chinese tourists.
Here's a quick overview of the unique modules the China Travel Dashboard encompasses:
- Travel Sentiment: This module features an exhaustive quarterly survey helmed by China Trading Desk, assessing the travel inclinations of potential Chinese outbound travellers, thereby providing a snapshot of emerging trends.
- Pre-Trip: Developed in partnership with VariFlight, this module delivers real-time travel data including daily airport traffic flow from all airports in China to a selected group of 25 countries around the world, providing a glimpse into preferred destinations.
- In-Trip: Partnering with UnionPay, this module offers an exclusive window into Chinese tourists' spending patterns and preferences while they're immersed in their travel experiences.
Subramania Bhatt, Founder & CEO of China Trading Desk, stated, "We are thrilled to bring this comprehensive tool to our esteemed clients. The China Travel Dashboard is a solid reflection of our relentless commitment to staying on the cutting edge of providing data that's most relevant for our advertisers and agencies. As the outbound travel market in China continues to expand, we are confident this tool will prove to be indispensable in aiding businesses and advertisers to effectively understand, reach, and engage with Chinese tourists."
The dashboard’s data allows businesses to formulate personalized marketing strategies, optimize ad scheduling, undertake destination marketing, predict upcoming trends, and facilitate product development. Notably, several renowned brands including a global luxury conglomerate and the world's largest hospitality chain, have beta-tested the Dashboard and acclaimed it as the most comprehensive tool to understand Chinese travel insights and behaviour.
For more information visit the China Travel Dashboard.
About China Trading Desk:
China Trading Desk is a marketing technology company enabling brands & agencies to help advertise in China & across the world. Our suite of products focuses on China advertising and Chinese travellers and enables advertisers to effectively reach out to their target audience. CTD works with some of the world’s most pioneering brands including Singapore Airlines, HSBC, LVMH Group, Qatar Airways, etc. We are headquartered in Singapore with offices in Hong Kong, Shanghai, Shenzhen, Guangzhou, and affiliates in Dubai, London and New York.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230724321638/en/
Contact information
China Trading Desk
Marketing Department
+6566992226
Hello@chinatradingdesk.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom